Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Merck Group

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA

              Contact the Supplier

              Lead Product(s): Pimasertib,DAY101

              Therapeutic Area: Oncology Product Name: MSC19363639B

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Day One Biopharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 23, 2021

              Details:

              Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B. Day One plans to study the combination of pimasertib and DAY101 in patients ≥12 years of age with advanced solid tumors.

              Affimed

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Affimed and Roivant Sciences Ink Licensing Agreement to Develop and Commercialize Novel Innate Cell Engagers for Multiple Cancer Targets

              Contact the Supplier

              Lead Product(s): AFM32

              Therapeutic Area: Oncology Product Name: AFM32

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Roivant Sciences

              Deal Size: $2,060.0 million Upfront Cash: $60.0 million

              Deal Type: Collaboration November 09, 2020

              Details:

              The collaboration grants Roivant a license to the preclinical molecule AFM32. The collaboration will also leverage Affimed’s proprietary Redirected Optimized Cell Killing (ROCK®) platform to generate ICE® molecules against targets not included in Affimed’s current pipeline.

              MorphoSys

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer

              Contact the Supplier

              Lead Product(s): MOR210,Undisclosed

              Therapeutic Area: Oncology Product Name: TJ210

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: I-Mab Biopharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 17, 2020

              Details:

              MOR210/TJ210 is a highly differentiated monoclonal antibody that is directed against complement factor C5a receptor 1 (C5aR1). The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210.

              PharmaCompass__DigitalAd